<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Hospira Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/hospira-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HSP) Hospira Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003</link>
		<comments>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:24:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86003</guid>
		<description><![CDATA[Hospira Inc.&#8217;s (HSP) third quarter preliminary results were below expectations due to continued manufacturing problems at the company&#8217;s Rocky Mountain facility. The facility is expected to continue functioning below full capacity through the remainder of 2011. The additional costs for manufacturing remediation resulted in lost sales, inventory loss and lower service levels. In addition, management cut its 2011 adjusted earnings guidance to $2.95-$3.05 from $3.90-$4.00. We have slashed our 2011 earnings estimate from $3.93 to $3.01 and our 2012 estimates from $4.47 to $2.85, in line with management&#8217;s action. Moreover, the Symbiq and Plum pump issues remain matters of concern. We have, therefore, downgraded our rating on Hospira from Neutral to Underperform. HOSPIRA INC (HSP): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058</link>
		<comments>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058#comments</comments>
		<pubDate>Fri, 27 May 2011 13:41:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75058</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million. The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US. The Medicines Company received a major boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Earnings Beat The Street &#8211; Backs Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495</link>
		<comments>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495#comments</comments>
		<pubDate>Tue, 03 May 2011 19:27:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[APAC]]></category>
		<category><![CDATA[APAC Customer Services Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72495</guid>
		<description><![CDATA[Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’ (SNY) cancer drug Taxotere which was launched in March 2011. Results were however 1 cent below the year-earlier earnings of 94 cents due to difficult year-over-year comparisons. Earnings in the prior-year quarter were boosted by strong margin contribution from US sales of Hospira’s generic version of Sanofi’s Eloxatin (oxaliplatin) which has been temporarily discontinued. Higher research and development expenses also affected earnings in the quarter. First quarter revenues of $1 billion were almost flat year over year. Total revenues beat the Zacks Consensus Estimate of $941 million. The top line was boosted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Company News for April 27, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544</link>
		<comments>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:30:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Central European Media Enterprises Limited]]></category>
		<category><![CDATA[CETV]]></category>
		<category><![CDATA[CH Robinson Worldwide Inc.]]></category>
		<category><![CDATA[CHRW]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[Mission West Properties Inc]]></category>
		<category><![CDATA[MSW]]></category>
		<category><![CDATA[Timken Company]]></category>
		<category><![CDATA[TKR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72544</guid>
		<description><![CDATA[•    Hospira (NYSE:HSP) reported Q1 EPS of $0.93, well ahead of the Zacks Consensus Estimate of $0.78 per share. Revenues for the quarter fell less by than a percent to $1.0 billion, topping the Zacks Consensus Estimate of $941.0 million •    Ford (NYSE:F) reported Q1 EPS of $0.61, beating the Zacks Consensus Estimate of $0.50 per share. Revenues for the quarter rose 17.8% year-over-year to $33.1 billion, higher than the Zacks Consensus Estimate of $30.188 billion •    Lockheed Martin Corp (NYSE:LMT) reported Q1 EPS of $1.55, above the Zacks Consensus Estimate for $1.51 per share. Revenues for the quarter increased 2.9% year-over-year to $10.63 billion, slightly lower than the Zacks Consensus Estimate of $10.644 billion •    Bearings and specialty steel manufacturer The Timken Co. (NYSE:TKR) raised its full year 2011 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat</title>
		<link>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288</link>
		<comments>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288#comments</comments>
		<pubDate>Tue, 22 Feb 2011 17:50:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67288</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of 24 cents and the year-ago loss of 57 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, up 17.3% at $119.6 million, surpassed the Zacks Consensus Estimate of $111 million. Full-year earnings came in at $1.15 per share, in-line with the Zacks Consensus Estimate and well above the year-ago loss of 46 cents. Full year revenues increased 8.3% to $437.6 million, well above the Zacks Consensus Estimate of $429 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter with US sales increasing 16.3% to $112 million. US sales benefited from continued demand in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Results Eclipsed by Sanofi-Aventis Deal</title>
		<link>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086</link>
		<comments>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086#comments</comments>
		<pubDate>Fri, 18 Feb 2011 16:44:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Chicago Rivet & Machine Company]]></category>
		<category><![CDATA[CVR]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67086</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported fourth quarter earnings of 71 cents per share (excluding one-time items but including the impact of stock-based compensation expense), a couple of cents below the Zacks Consensus Estimate, but significantly above the year-earlier earnings of 17 cents. Excluding the impact of stock-based compensation expense, fourth quarter earnings came in at 82 cents, well above the year-ago period earnings of 29 cents. Results were in line with the preliminary outlook provided by the company in Jan 2011. Fourth quarter results were driven by the increase in shipments of lead product, Cerezyme, as well as Fabrazyme, contributions from other product lines and cost savings. Fourth quarter revenues increased 23% to $1.15 billion. Although revenues were slightly short of the Zacks Consensus Estimate of $1.16 billion, we were pleased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADS) Company News for February 03, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/03/ads-company-news-for-february-03-2011-corporate-summary/66303</link>
		<comments>http://www.stockbloghub.com/2011/02/03/ads-company-news-for-february-03-2011-corporate-summary/66303#comments</comments>
		<pubDate>Thu, 03 Feb 2011 22:15:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Credit Services]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Avery Dennison Corporation]]></category>
		<category><![CDATA[AVY]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Intevac Inc.]]></category>
		<category><![CDATA[IVAC]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[YUM]]></category>
		<category><![CDATA[Yum! Brands Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66303</guid>
		<description><![CDATA[• Avery Dennison (NYSE:AVY) reported Q4 EPS of $0.98, missing the Zacks Consensus of $0.97 per share by a penny. Revenues for the quarter rose 8% year-over-year to $1.64 billion, ahead of the Zacks Consensus Estimate of $1.60 billion • Hospira (NYSE:HSP) reported Q4 EPS of $0.77, lower than the Zacks Consensus Estimate of $0.93 per share. Revenues for the quarter fell 6% year-over-year to $992.1 million, missing the Zacks Consensus Estimate of $1.035 billion • Yum! Brands (NYSE:YUM) reported Q4 EPS of $0.63, ahead of the Zacks Consensus Estimate of $0.60 per share. Revenues for the quarter rose 5.6% year-over-year to $3.56 billion, ahead of the Zacks Consensus Estimate of $2.403 billion • News Corp. (NASDAQ:NWSA) reported adjusted Q2 EPS of $0.29, ahead of the Zacks Consensus Estimates of $0.28 per share. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/03/ads-company-news-for-february-03-2011-corporate-summary/66303/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Receives Good Patent News</title>
		<link>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847</link>
		<comments>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847#comments</comments>
		<pubDate>Fri, 10 Dec 2010 20:18:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=61847</guid>
		<description><![CDATA[We recently reiterated our Outperform recommendation on The Medicines Company (MDCO). In August 2010, The Medicines Company received good news with the US District Court for the Eastern District of Virginia ordering the US Patent and Trademark Office (PTO) to treat The Medicines Company’s patent term extension application for lead product, Angiomax, as having been filed on a timely basis. Following this ruling, the PTO granted a one-year interim extension of the principal US patent that covers Angiomax. The extension will provide exclusivity until August 13, 2011 (February 2012 including 6-month pediatric exclusivity). With the US Solicitor General and the Government deciding against appealing the Court’s ruling, a major overhang on The Medicines Company has been removed. Previously, we were expecting Angiomax to start facing generics from late 2010. But, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895</link>
		<comments>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895#comments</comments>
		<pubDate>Mon, 02 Aug 2010 21:52:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44895</guid>
		<description><![CDATA[Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in the year-earlier period. The Zacks Consensus Estimate for second-quarter revenue is $1,006 million as against $957 million reported in the year-ago quarter. First-Quarter Recap Hospira Inc.’s first-quarter fiscal 2010 earnings (excluding special items) of 94 cents per share handsomely beat the Zacks Consensus Estimate of 72 cents and the year-ago earnings of 60 cents. On a reported basis, the company earned 84 cents per share, down 18.4% from the year-ago earnings. Revenues for the quarter climbed 17.2% year over year to $1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Company Tops Street Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219</link>
		<comments>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219#comments</comments>
		<pubDate>Fri, 30 Jul 2010 03:39:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45219</guid>
		<description><![CDATA[The Medicines Co. (MDCO) reported a second-quarter profit of 27 cents per share Incorporatedluding the impact of stock-based compensation expense. Second quarter profit was well above the Zacks Consensus Estimate of 23 cents and the year-ago earnings of 8 cents. Performance was boosted by higher revenues and lower operating expenses. The company completed its cost reduction program by cutting more than 100 jobs and expects to achieve annual savings in the range of $14.5 million–$16.5 million. Meanwhile, revenues increased 5.7% to $110.1 million, $3 million above the Zacks Consensus Estimate. Angiomax continued to see strong demand during the quarter. While Angiomax sales in the US increased 5.7% to $104.4 million, sales in ex-US markets increased to $5.8 million. Strong growth in countries like Italy, France, Scandinavia, Benelux and the United ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257</link>
		<comments>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257#comments</comments>
		<pubDate>Thu, 22 Jul 2010 02:02:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44257</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of 36 cents and the year-earlier earnings of 64 cents. Excluding the impact of stock-based compensation expense, earnings came in at 18 cents. With the company yet to emerge from manufacturing problems, we were not surprised to see the dismal second quarter results. Second quarter revenues declined 12% to $1.08 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $350.5 million, down 40%. Production and supply of two products, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Extends Javelin Pharmaceuticals Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865</link>
		<comments>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865#comments</comments>
		<pubDate>Tue, 25 May 2010 03:25:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[JAV]]></category>
		<category><![CDATA[Javelin Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37865</guid>
		<description><![CDATA[Recently, Hospira (HSP) extended its tender offer for acquiring Javelin Pharmaceuticals (JAV). The offer, which was supposed to expire on May 18, has been extended till June 2, 2010 as all the conditions of the deal have not yet been met. Viewing the uncertainty surrounding the closure of the deal, shares of Javelin Pharma plunged subsequent to the announcement. In April 2010, Hospira announced its intention to acquire Javelin for $2.20 per share or approximately $145 million. If the deal with Hospira does not get through, it will be a major setback for Javelin. In December 2009, Myriad Pharmaceuticals (MYRX) had decided to acquire Javelin in a stock-swap deal. However, Javelin decided to terminate this agreement in April 2010. The termination has resulted in Javelin paying $4.4 million to Myriad ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Announces Intentions to Acquire Javelin Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447</link>
		<comments>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447#comments</comments>
		<pubDate>Wed, 21 Apr 2010 20:57:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JAV]]></category>
		<category><![CDATA[Javelin Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34447</guid>
		<description><![CDATA[Recently, Hospira (HSP) announced its intention to acquire Javelin Pharmaceuticals (JAV) for $2.20 per share or approximately $145 million. Hospira expects to initiate the tender offer for all the outstanding shares of Javelin shortly. The acquisition of Javelin will provide Hospira with access to Javelin’s lead product candidate, Dyloject, a post-operative pain management drug. The drug is awaiting approval from the US Food and Drug Administration (FDA). A final decision is likely by October 3, 2010. As a non-opioid analgesic, Dyloject scores over traditional intravenous opioids, which are associated with significant adverse events in pain management. Hospira will gain global rights to Dyloject other than in Europe, where rights are licensed to a third party. Hospira plans to market the product in the US, Canada, Latin America and the Asia-Pacific ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPIX) Cumberland Pharmaceuticals&#8217; Ibuprofen Safety and Efficacy Beats Acetaminophen</title>
		<link>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842</link>
		<comments>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842#comments</comments>
		<pubDate>Wed, 14 Apr 2010 22:37:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33842</guid>
		<description><![CDATA[Recently, Cumberland Pharmaceuticals Inc. (CPIX) announced results from a meta-analysis comparing the safety and efficacy of Caldolor (ibuprofen) and acetaminophen. The data, which was published in the March edition of The Annals of Pharmacotherapy, revealed that ibuprofen was more effective than acetaminophen for the treatment of pain and fever. The newly published meta-analysis was based on 85 published studies that compared oral ibuprofen with oral acetaminophen for analgesic efficacy, antipyretic efficacy and safety in adult as well as pediatric populations. Cumberland stated that the data reinforced the findings from previously published studies on the efficacy of Caldolor injection for the treating pain and fever. As a reminder, the US Food and Drug Administration (FDA) had approved Caldolor, the intravenous formulation of ibuprofen, in June 2009. The product, launched in September ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Settles Sanofi-Aventis Patent Dispute</title>
		<link>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827</link>
		<comments>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827#comments</comments>
		<pubDate>Tue, 06 Apr 2010 04:00:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32827</guid>
		<description><![CDATA[Hospira (HSP) has reached an agreement with Sanofi-Aventis (SNY) to settle a patent dispute for the US sales of oxaliplatin injection, a generic version of Sanofi-Aventis&#8217; Eloxatin. Per the settlement, Hospira will not sell oxaliplatin injection in the US until June 30, 2010. However, the drug can be re-launched on Aug. 9, 2012. Hospira has been involved in a patent litigation with Sanofi-Aventis for the past few months. Although Hospira received a favorable decision in August 2009, the decision was later vacated. Eloxatin, meant for the treatment of advanced colorectal cancer and stage III colon cancer patients after surgery, recorded US sales of €677 million in 2009. Apart from Hospira, Sanofi settled its Eloxatin patent dispute with other generic manufacturers such as Teva Pharmaceuticals (TEVA), Fresenius Kabi and Sandoz, Novartis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely</title>
		<link>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996</link>
		<comments>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996#comments</comments>
		<pubDate>Sat, 27 Mar 2010 20:43:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31996</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period, it would also require Genzyme to make payments to the government and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Likely to See FDA Enforcement Action</title>
		<link>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768</link>
		<comments>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:53:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31768</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period of time, it would also require Genzyme to make payments to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Earnings Comes in Well Ahead of Expectations</title>
		<link>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130</link>
		<comments>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:27:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27130</guid>
		<description><![CDATA[Hospira (HSP) reported strong fourth quarter and full year 2009 results. Earnings per share (EPS) came in at 87 cents, well above the Zacks Consensus Estimate of 70 cents and the year-ago earnings of 78 cents. Revenues recorded a year-over-year increase of 15.5% to $1.1 billion, primarily driven by growth in Specialty Injectable Pharmaceuticals (SIP). However, after taking into account certain charges related to its operations and restructuring initiatives, EPS declined 10.8% to 58 cents. For the full year, the company reported revenues and EPS of $3.9 billion (up 6.9%) and $3.11(up 22.9%), respectively. While SIP revenues increased 20.3% from the year-ago period (at constant exchange rates, CER) to $578.3 million, revenues from the Other Pharma segment increased 4.8% to $197.2 million. The strong growth in the SIP segment was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Carries Out Restructuring Plan</title>
		<link>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007</link>
		<comments>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:42:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25007</guid>
		<description><![CDATA[Hospira (HSP) is carrying out its restructuring plans in an attempt to reduce its operating expenses. The company is reducing its workforce by 10% (1400-1500 employees), which would result in savings of $110 -$140 million by 2011. This initiative, named ‘Project Fuel’, was announced by the company earlier in March 2009. Management reiterated the restructuring plan at the recently held JP Morgan Healthcare Conference. The main aim of the project was to optimize the product portfolio, evaluate non-strategic assets and streamline the organizational structure. During the third quarter conference call, management announced that they are on track to meet the milestones, having notified almost 60% of the targeted 1400–1500 positions. In order to hive off the non-strategic assets, in July 2009, Hospira decided to sell its critical care business to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme&#8217;s Revenues Decline</title>
		<link>http://www.stockbloghub.com/2010/01/13/genz-genzymes-revenues-decline/24875</link>
		<comments>http://www.stockbloghub.com/2010/01/13/genz-genzymes-revenues-decline/24875#comments</comments>
		<pubDate>Thu, 14 Jan 2010 00:56:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24875</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently reported preliminary revenues for the fourth quarter and full year ended December 31, 2009. With the company facing manufacturing problems from mid 2009, we were not surprised to see fourth quarter revenues decline 8% to $1.08 billion. Full year revenues declined 2% to $4.5 billion. Genzyme’s Genetic Diseases segment was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The production and supply of two products – Cerezyme and Fabrazyme ? were mainly affected by the temporary shutdown. Revenues from the segment declined 43% to $317 million. For the full year, revenues from this segment declined 20% to $1.8 billion. Sales of the lead product Cerezyme declined 65% to $106 million in the fourth quarter. For the year, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/genz-genzymes-revenues-decline/24875/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Hospira Inks Manufacturing Deal with Genzyme</title>
		<link>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213</link>
		<comments>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213#comments</comments>
		<pubDate>Tue, 05 Jan 2010 22:25:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24213</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) has entered into a contract manufacturing agreement with Hospira (HSP) for its key drugs Incorporatedluding Cerezyme and Fabrazyme. We believe this move has been taken to reduce the impact of the company’s manufacturing plant-related issues on the supply of its products. Any financial detail of the deal, which is set to expire in 2015, has not been disclosed. The deal has yet to receive regulatory approval for the manufacturing of these drugs. Genzyme has been under significant pressure following the shutdown of its Allston manufacturing facility in June 2009. The shutdown is a major setback as three drugs Incorporatedluding Cerezyme, were being manufactured at the facility. The closure of the plant has affected Genzyme’s financial performance significantly with third quarter revenues declining 9% to $1.06 billion. Last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Aquires Pharmaceuticals Business</title>
		<link>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996</link>
		<comments>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996#comments</comments>
		<pubDate>Wed, 16 Dec 2009 23:10:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22996</guid>
		<description><![CDATA[Hospira (HSP) has been making certain strategic moves in the recent past; the latest deal will establish its presence in one of the most sought after emerging market ? India. Hospira decided to acquire India-based Orchid Chemicals’ generic injectable finished-dosage form pharmaceuticals business for approximately $400 million. The transaction, expected to be completed by the first quarter of 2010, will be EPS neutral for Hospira in 2010, excluding the associated costs. The acquisition involves Orchid&#8217;s beta-lactam antibiotics (a class of drugs with a wide spectrum of antibacterial activity) manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and pharmaceutical research and development (R&#38;D) facility at Irungattukottai, Chennai, as well as its generic injectable product portfolio and pipeline. The manufacturing site has necessary approvals from international regulatory authorities Incorporatedluding the US Food ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPIX) Cumberland Pharmaceuticals Beats Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523</link>
		<comments>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523#comments</comments>
		<pubDate>Mon, 30 Nov 2009 16:22:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21523</guid>
		<description><![CDATA[Cumberland Pharmaceuticals Inc. (CPIX) reported third quarter earnings of 10 cents per share, well above the Zacks Consensus Estimate of 1 cent. Revenues for the quarter came in at $13.6 million as against $8.6 million in the comparable quarter of 2008, up 58%. The increase in revenues for the quarter was attributable to the initial sales from Caldolor injection, the intravenous formulation of ibuprofen, coupled with the increased usage of Acetadote, an injectable drug intended to counter the overdoses of acetaminophen. The U.S. Food and Drug Administration (FDA) approved Caldolor in Jun 2009. The product, launched in Sep, is the first injectable product available in the U.S. for treating pain and fever. The injection is used primarily for treating hospitalized patients who cannot receive oral drugs for reducing pain and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Surges Ahead</title>
		<link>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936</link>
		<comments>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936#comments</comments>
		<pubDate>Wed, 28 Oct 2009 03:49:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18936</guid>
		<description><![CDATA[Hospira (HSP) reported third quarter earnings of 90 cents per share, well above both the Zacks Consensus Estimate of 68 cents and 63 cents per share in the year-ago period. Revenues increased 8.9% to $1 billion, primarily driven by growth in Specialty Injectable Pharmaceuticals (SIP). SIP revenues increased 25.6% from the year-ago period (at constant exchange rates, CER) to $575.7 million while revenues from the Other Pharma segment came down 8.4% to $157.4 million. The strong growth in the SIP segment was driven by the launch of the generic oncolytic oxaliplatin in the quarter. Unlike the previous quarter, revenues from Medication Management Systems (MMS) increased 1.7% year over year at CER to $162.6 million. However, Other Devices continued to fall in the reported quarter and recorded revenues of $111.8 million, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Ups 2009 Earnings Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523</link>
		<comments>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523#comments</comments>
		<pubDate>Sat, 03 Oct 2009 21:42:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16523</guid>
		<description><![CDATA[Lake Forest, Illinois-based specialty pharmaceutical products maker Hospira (HSP) recently raised its 2009 outlook. The company now sees earnings in the range of $2.80 to $2.85 per share up from its earlier guidance of $2.70 to $2.75. Annual revenue is expected to rise by 5 to 7% compared to the earlier expected growth of 4 to 6% on a constant currency basis. Hospira also boosted its 2009 outlook for gross margin, operating margin and cash flow from operations to 39.5%-40.5%, 18%-19% and $610 million-$660 million, respectively. Hospira said it is confident that its cost-cutting and restructuring initiative, Project Fuel, would improve profitability through 2011. The company’s restructuring plan consists of a 10% reduction in workforce and realignment of its product portfolio including the sale of non-core businesses. It has already ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Inc. &#8211; Growing Sales of Pharmaceutical Delivery Systems</title>
		<link>http://www.stockbloghub.com/2009/09/22/hsp-hospira-inc-growing-sales-of-pharmaceutical-delivery-systems/15788</link>
		<comments>http://www.stockbloghub.com/2009/09/22/hsp-hospira-inc-growing-sales-of-pharmaceutical-delivery-systems/15788#comments</comments>
		<pubDate>Tue, 22 Sep 2009 21:18:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15788</guid>
		<description><![CDATA[Hospira Inc (HSP) shares are being driven by growing sales and continue to pressure the newly-set 52-week high. Company Description Hospira makes pharmaceutical delivery systems, primarily injectable. The company provides products and systems to hospitals, wholesalers, delivery networks, clinics, home healthcare providers, and long-term care facilities. Healthy Profits Second-quarter results were released on Jul 29 and included sales of $957 million, up from $902 million in the same period last year. This equated to earnings per share of 73 cents, 22% higher than the Zacks Consensus Estimate of 60 cents. This was Hospira&#8217;s third consecutive earnings surprise, with a 12% average. The company has just 3 misses in the past 5 years of reports. Raising Guidance As sales continued to grow following the report, the company raised guidance on Sep ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/22/hsp-hospira-inc-growing-sales-of-pharmaceutical-delivery-systems/15788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Ups 2009 Guidance</title>
		<link>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635</link>
		<comments>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:56:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15635</guid>
		<description><![CDATA[Lake Forest, Illinois-based specialty pharmaceutical products maker Hospira (HSP) recently raised its 2009 outlook. The company now sees earnings in the range of $2.80 to $2.85 per share up from its earlier guidance of $2.70 to $2.75. Annual revenue is expected to rise by 5 to 7% compared to the earlier expected growth of 4 to 6% on a constant currency basis. Hospira also boosted its 2009 outlook for gross margin, operating margin and cash flow from operations to 39.5%-40.5%, 18%-19% and $610 million-$660 million, respectively. Hospira said it was confident that its cost cutting and restructuring initiative, Project Fuel, would improve profitability through 2011. The company’s restructuring plan consists of a 10% reduction in workforce and realignment of its product portfolio including the sale of non-core businesses. It has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira &#8211; FDA reinstated approval for Hospira’s generic version of Eloxatin</title>
		<link>http://www.stockbloghub.com/2009/08/21/hsp-hospira-fda-reinstated-approval-for-hospira%e2%80%99s-generic-version-of-eloxatin/13070</link>
		<comments>http://www.stockbloghub.com/2009/08/21/hsp-hospira-fda-reinstated-approval-for-hospira%e2%80%99s-generic-version-of-eloxatin/13070#comments</comments>
		<pubDate>Fri, 21 Aug 2009 19:01:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13070</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) reinstated the previously suspended approval for Hospira’s (HSP) generic version of Eloxatin (chemotherapy agent), giving the company some relief for the time being. The Eloxatin issue has been in the news for the past few days ever since Hospira received the approval to launch its generic version of the drug, which is manufactured by French giant Sanofi-Aventis (SNY). Along with Hospira, the largest generics player Teva Pharmaceuticals (TEVA) also received the approval to sell its generic version of the drug. However, soon after granting approval, the FDA ordered both Teva and Hospira to stop shipment of the drug pending patent infringement litigation filed by Sanofi-Aventis against both the companies. Recently the court order was dissolved following which both Teva and Hospira resumed shipment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/hsp-hospira-fda-reinstated-approval-for-hospira%e2%80%99s-generic-version-of-eloxatin/13070/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Major Setback for Hospira Incorporated</title>
		<link>http://www.stockbloghub.com/2009/08/19/hsp-major-setback-for-hospira-incorporated/12678</link>
		<comments>http://www.stockbloghub.com/2009/08/19/hsp-major-setback-for-hospira-incorporated/12678#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:23:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12678</guid>
		<description><![CDATA[In a major setback for Hospira Inc., (HSP) the company had to stop the shipment of its generic version of chemotherapy drug Eloxatin (oxaliplatin), within a few days of receiving regulatory approval. Apart from Hospira, Teva Pharmaceuticals (TEVA), the largest generic player also received the approval to sell its generic version of Eloxatin, which is manufactured by Sanofi-Aventis (SNY). Eloxatin, meant for the treatment of advanced colorectal cancer and stage III colon cancer patients after surgery, recorded US sales of $1.4 billion in 2008. French giant, Sanofi-Aventis is suing both Hospira and Teva for patent infringement. Although in June 2009, a US District Court in New Jersey ruled in favor of Hospira and announced that the generic drug did not infringe the patent held by Sanofi-Aventis, the latter has appealed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/hsp-major-setback-for-hospira-incorporated/12678/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

